Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials

Fig. 3

Postprogression overall survival by initial postprogression treatment. Kaplan–Meier curves of ppOS in all pooled patients receiving initial postprogression treatment with immunotherapy or targeted therapy (n = 300). ppOS postprogression overall survival

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us